创伤性脑损伤后左乙拉西坦预防癫痫的给药策略评价
该回顾性单中心队列纳入2013年7月1日至2019年9月1日期间≥18岁、诊断创伤性脑损伤并接受左乙拉西坦早期预防创伤后癫痫的住院患者866例(≤1000 mg/日组289例、1500 mg/日组137例、≥2000 mg/日组440例),采用重叠倾向评分加权控制混杂。加权后早期创伤后癫痫累积发生率分别为≤1000 mg/日组2.9%、1500 mg/日组8.8%、≥2000 mg/日组9%。与≤1000 mg/日组相比,1500 mg/日组和≥2000 mg/日组的早期创伤后癫痫亚分布风险分别增加209%和216%,但差异均无统计学意义。作者结论为三种给药策略在创伤性脑损伤后7天内早期创伤后癫痫累积发生率上无统计学显著差异,加权后≤1000 mg/日组早期创伤后癫痫、无癫痫死亡及院内死亡率最低。
要点
- 866例创伤性脑损伤患者中,加权后早期创伤后癫痫累积发生率:≤1000 mg/日组2.9%、1500 mg/日组8.8%、≥2000 mg/日组9%,三组间无统计学显著差异。
- 与≤1000 mg/日组相比,1500 mg/日组早期创伤后癫痫亚分布风险增加209%,≥2000 mg/日组增加216%,但均未达统计学显著。
- 加权后≤1000 mg/日左乙拉西坦组的早期创伤后癫痫、无癫痫死亡及院内死亡率最低。
- 研究为回顾性单中心队列,采用重叠倾向评分加权控制混杂,结论需结合患者个体情况解读。
适用人群与场景
- ≥18岁、诊断为创伤性脑损伤并接受左乙拉西坦早期预防创伤后癫痫的住院患者,纳入时间为2013年7月1日至2019年9月1日。
处置流程与药物剂量
- 左乙拉西坦用于创伤性脑损伤后早期预防创伤后癫痫,研究比较的维持剂量策略为≤1000 mg/日、1500 mg/日、≥2000 mg/日。
研究设计与关键结果
- 研究类型:回顾性单中心队列研究;最终纳入866例(≤1000 mg/日组289例、1500 mg/日组137例、≥2000 mg/日组440例),采用重叠倾向评分加权。
- 主要终点:加权后早期创伤后癫痫累积发生率≤1000 mg/日组2.9%、1500 mg/日组8.8%、≥2000 mg/日组9%。
- 与≤1000 mg/日组相比,1500 mg/日组早期创伤后癫痫亚分布风险增加209%,≥2000 mg/日组增加216%,差异均无统计学意义。
- 次要终点:加权后≤1000 mg/日组早期创伤后癫痫、无癫痫死亡及院内死亡率最低。
证据类型、等级与局限
- 证据类型:回顾性单中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:三种左乙拉西坦给药策略在创伤性脑损伤后7天内早期创伤后癫痫累积发生率上无统计学显著差异;加权后≤1000 mg/日组早期创伤后癫痫、无癫痫死亡及院内死亡率最低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although levetiracetam has been increasingly used as an alternative to phenytoin for early posttraumatic seizure prophylaxis following traumatic brain injury (TBI), an optimal dosing strategy has not been elucidated. The objective of this study is to determine whether different dosing strategies of levetiracetam are associated with the incidence of early posttraumatic seizures when used as prophylaxis following TBI.
METHODS: This retrospective single-center cohort study included admitted patients ≥ 18 years of age with a diagnosis of TBI and receiving levetiracetam for early posttraumatic seizure prophylaxis between July 1, 2013, and September 1, 2019. The primary outcome of this study was to evaluate three different dosing strategies of levetiracetam (≤ 1000 mg/day, 1500 mg/day, and ≥ 2000 mg/day) and associated rates of early posttraumatic seizures. Secondary outcomes were to summarize absolute total daily maintenance doses of levetiracetam among patients who experienced early posttraumatic seizures compared with those who did not, to determine the impact of three different dosing strategies on hospital length of stay and in-hospital mortality, and to assess patient-specific variables on the occurrence of posttraumatic seizures. Overlap propensity score weighting was used to address the potential for confounding.
RESULTS: Of the 1287 patients who received levetiracetam for early posttraumatic seizure prophylaxis during the study time frame, 866 patients met eligibility criteria and were included in the study cohort (289 patients in the ≤ 1000 mg/day group, 137 patients in the 1500 mg/day group, and 440 patients in the ≥ 2000 mg/day group). After weighting, the cumulative incidence of early posttraumatic seizure was 2.9% in the ≤ 1000 mg/day group, 8.8% in the 1500 mg/day group, and 9% in the ≥ 2000 mg/day group. The 1500 mg/day and ≥ 2000 mg/day levetiracetam groups had a 209% and 216% increase in the subdistribution hazard of early posttraumatic seizures compared with the ≤ 1000 mg/day levetiracetam group, respectively, but these differences were not statistically significant.
CONCLUSIONS: In conclusion, the results of this study demonstrate no statistically significant difference in the cumulative incidence of early posttraumatic seizures within 7 days of TBI between three different levetiracetam dosing strategies. After weighting, the ≤ 1000 mg/day levetiracetam group had the lowest rates of early posttraumatic seizures, death without seizure, and in-hospital mortality.
参考来源
- Ohman K, Kram B, Schultheis J, et al. Evaluation of Levetiracetam Dosing Strategies for Seizure Prophylaxis Following Traumatic Brain Injury. Neurocrit Care. 2022. PMID: 36167949. doi:10.1007/s12028-022-01599-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。